With the first product launched in Chinese market in 1996, Lundbeck, headquartered in Beijing, has officially settled in China since 2007. A series of medicines for brain diseases have been launched in Chinese market, including Lexapro® (depression), Ebixa® (Alzheimer’s disease), Cipramil® (depression) and Deanxit® (depression).
Lundbeck in China:
Lundbeck established its affiliate in Beijing in 2007, formally started the commercial operation in China. Our focused four disease areas are depression, schizophrenia, Alzheimer’s Disease and Parkinson’s Disease. We are establishing Lundbeck as a strong and independent CNS leader in China by improving the lives of patients. We stay true to our principles: focused, passionate, and responsible.
In the past years, Lundbeck China has been dedicated to increase CNS awareness and education in psychiatry and neurology, and launched a number of disease education programs and academic exchange projects. Lundbeck is also highly committed to contributing to the development of China's healthcare career and public hospital reform, and supporting the healthcare and hospital management capacity-building and academic exchanges, and hopes to eventually serve the continuous improvement of medical treatment quality and patients’ satisfaction.